Lobbying disclosures · Lobbying report
MRK: third_quarter 2026 lobbying report
Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs.
Follow MRK- Became public
- Oct 19, 2026, 6:35 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 10:50 AM EST
Why this is connected
Exact legal-name match: Merck & Co., Inc. (https://www.sec.gov/Archives/edgar/data/310158/).
Reported lobbying amounts
Income: $70,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/e5ececa2-6577-48f8-b938-e7cad1134f8b/","filing_uuid":"e5ececa2-6577-48f8-b938-e7cad1134f8b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/e5ececa2-6577-48f8-b938-e7cad1134f8b/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Greg D'Angelo","dt_posted":"2026-10-19T18:35:08-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 13th St. NW","registrant_address_2":"Suite 250 N","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":293335,"url":"https://lda.gov/api/v1/registrants/293335/","house_registrant_id":37338,"name":"THE NICKLES GROUP, LLC","description":"Consulting firm.","address_1":"601 13th St. NW","address_2":"Suite 250 N","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATHLEEN MCGHEE","contact_telephone":"+1 202-742-6990","dt_updated":"2026-07-06T11:19:03.627222-04:00"},"client":{"id":178554,"url":"https://lda.gov/api/v1/clients/178554/","client_id":1005231,"name":"MERCK & CO. INC.","general_description":"Manufacturer of pharmaceuticals","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-01-22"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":89965,"prefix":null,"prefix_display":null,"first_name":"GREG","nickname":null,"middle_name":null,"last_name":"D'ANGELO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":103387,"prefix":null,"prefix_display":null,"first_name":"BRETT","nickname":null,"middle_name":null,"last_name":"BAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26331,"prefix":null,"prefix_display":null,"first_name":"MARY","nickname":null,"middle_name":"BETH","last_name":"SAVARY TAYLOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":89965,"prefix":null,"prefix_display":null,"first_name":"GREG","nickname":null,"middle_name":null,"last_name":"D'ANGELO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":103387,"prefix":null,"prefix_display":null,"first_name":"BRETT","nickname":null,"middle_name":null,"last_name":"BAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26331,"prefix":null,"prefix_display":null,"first_name":"MARY","nickname":null,"middle_name":"BETH","last_name":"SAVARY TAYLOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":89965,"prefix":null,"prefix_display":null,"first_name":"GREG","nickname":null,"middle_name":null,"last_name":"D'ANGELO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":20062,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"JONES HENSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150500,"prefix":null,"prefix_display":null,"first_name":"MOLLY","nickname":null,"middle_name":null,"last_name":"FROMM","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to tariffs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":89965,"prefix":null,"prefix_display":null,"first_name":"GREG","nickname":null,"middle_name":null,"last_name":"D'ANGELO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":20062,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"JONES HENSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150500,"prefix":null,"prefix_display":null,"first_name":"MOLLY","nickname":null,"middle_name":null,"last_name":"FROMM","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in MRK
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 2, 2026 · disclosed Nov 5, 2026 · Dependent
- Oct 7, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
Sold (partial) Merck & Co. MRK
$1K–$15K · Traded Sep 24, 2026 · disclosed Oct 7, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 9, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Sep 9, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
$15K–$50K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 30, 2026$1K–$15K
Rep. Keith Self (R-TX-3)
$1K–$15K · Traded Jan 10, 2025 · disclosed Jun 30, 2026 · filed 536 days later
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.